Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 857 posts found.

Novartis’ Mayzent granted license by the European Medicines Agency

January 21, 2020
Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis

The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …

News

NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns

January 20, 2020
Sales and Marketing Bayer, Cancer, NICE, Vitravki

UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …

News
lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

January 16, 2020
Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …

News

NICE shoots down Keytruda in head and neck cancer over data concerns

January 16, 2020
Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma

It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …

News

Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

January 15, 2020
Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …

News
47028496254_21a33b62df_b

NICE rules against the use of Akcea’s Waylivra in the NHS

January 3, 2020
Medical Communications Akcea, European Commission, FCS, NHS, NICE

NICE has not recommended Akcea’s drug Waylivra (volanesorsen) to be used for the treatment of Familial Chylomicronaemia Syndrome (FCS) in …

News
merck__co

FDA advisory panel back Merck & Co.’s Keytruda treatment for bladder cancer

December 18, 2019
Research and Development FDA, Merck, Merck and Co, NHS, NICE, keytruda

An FDA advisory committee voted 9 to 4 in favour of recommending Merk and Co’s Keytruda (pembrolizumab) for treatment in …

News

NICE reverses previous decision to recommend Vifor Pharma’s Veltassa for NHS treatment of hyperkalaemia

December 16, 2019
Sales and Marketing NHS, NICE, Veltassa, Vifor pharma

It has emerged that NICE has awarded its recommendation to Vifor Pharma’s Veltassa (patiromer) for treating hyperkalaemia, a condition classified …

News

Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease

December 12, 2019
Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales

Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …

News

NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases

December 2, 2019
Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma

NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …

News
pfizer_building_logo1_19

Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

November 28, 2019
Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …

News

NICE greenlights Consilient Health’s Elmiron for bladder pain syndrome

November 14, 2019
Sales and Marketing NICE, consilient health, elmiron, pharma

NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of bladder pain syndrome (BPS), it …

News

Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

October 11, 2019
Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …

News

NICE recommends pentosan polysulfate sodium for NHS treatment of bladder pain syndrome

October 10, 2019
Sales and Marketing NHS, NICE, bladder pain syndrome, pentosan polysulfate sodium

NICE has chosen to recommend pentosan polysulfate sodium, it has emerged, for use on the NHS in the treatment of …

News
rocherooflr

NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

October 3, 2019
Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024